

Provided by:



Multidisciplinary Tumor Board at the Rena Rowan Breast Center 2026-2027

Multidisciplinary Tumor Board at the Rena Rowan Breast Center 2026-2027 - 7/16/2026

July 16, 2026

8:00 AM - 9:00 AM

Online

Target Audience

This program has been designed for INTERNAL MEDICINE - Medical Oncology, PATHOLOGY - CLINICAL, RADIATION ONCOLOGY, SURGERY - Complex General Surgical Oncology

Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss patient's treatment plan amongst members of the care team
- 2 Describe how to implement up to date methods to diagnose and treat the patient's breast malignancy
- 3 Describe the standard of care for the management of the patients presented as reflected in national practice guidelines

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit:

Physicians: Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is for **1.00** contact hours.

Pharmacists: This activity is not approved for pharmacy contact hours.

PAs: Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for **1.00** AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

Approved for (PSRM) patient safety/risk management designation

Acknowledgement of Commercial Support*: None

For more information, please contact
Hailey Gallone
(215) 220-9726
hgallone@upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships(RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Angela Bradbury, MD	Other Planning Committee Member	Grant or research support-Astra Zeneca Pharmaceuticals (Relationship has ended) - 03/08/2026
ritu p chakrabarti, MD	Co-Director, Faculty	Nothing to disclose - 06/03/2026
Amy Clark, MD, MD, MSCE	Other Planning Committee Member	Grant or research support-Eli Lilly Grant or research support-Merck & Co Grant or research support-Novartis / Amgen (Relationship has ended) Honoraria-GE Healthcare (Relationship has ended) - 06/05/2026
Angela DeMichele, MD	Other Planning Committee Member	Nothing to disclose - 07/30/2025
Stephanie Dipaolo, NP	Nurse Planner	Nothing to disclose - 02/02/2026
Susan Domchek, MD	Other Planning Committee Member	Nothing to disclose - 01/23/2026
Gary M Freedman, MD	Other Planning Committee Member	Nothing to disclose - 06/05/2026
Madiha Gilani, MBBS	Other Planning Committee Member	Nothing to disclose - 04/15/2026
Saya Jacob, MD	Other Planning Committee Member	Nothing to disclose - 01/22/2026
Rachel Jankowitz, MD	Course Director	Nothing to disclose - 08/11/2025
Hayley Knollman, MD	Other Planning Committee Member	Nothing to disclose - 03/04/2026
Kimberley Lee, MD	Other Planning Committee Member	Membership on Advisory Committees or Review Panels, Board Membership, etc.-

		Novartis / Amgen (Relationship has ended) - 03/05/2026
Igor Makhlin, MD	Other Planning Committee Member	Consulting Fee-MJH Life Sciences (Relationship has ended) Consulting Fee-Astra Zeneca Pharmaceuticals (Relationship has ended) - 10/07/2025
Kimberly Molinari, CRNP, MSN	Nurse Planner	Nothing to disclose - 03/24/2026
Sara Muir, PA-C	Physician Assistant Planner	Nothing to disclose - 03/18/2026
Payal D Shah, MD	Other Planning Committee Member	Advisor-Astra Zeneca Pharmaceuticals Advisor-Daiichi Sankyo (Relationship has ended) Advisor-Gilead Sciences, Inc Advisor-Biotheranostics (Relationship has ended) - 08/01/2025
Eleanor P Taranto, MD	Other Planning Committee Member	Nothing to disclose - 10/07/2025
Amanda Ward, CRNP RN	Nurse Planner	Nothing to disclose - 01/22/2026

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected